Benzinga | Feb 1, 2021 06:51AM EST

ANI Pharmaceuticals Announces Launch of Prazosin Hydrochloride Capsules

ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced the launch of Prazosin HCl Capsules USP, 1mg and 2mg, following the U.S. Food and Drug Administration's ("FDA") approval of the Company's prior approval supplement application ("PAS").

The current annual U.S. market for Prazosin 1mg and 2mg strengths is approximately $46.2 million, according to IQVIA/IMS Health.

"Launch of Prazosin HCl is ANI's fourteenth re-commercialization of a previously discontinued abbreviated new drug application ("ANDA") product. The launch underscores our capabilities and commitment to capture the full value of our product portfolio and manufacturing capabilities," stated Nikhil Lalwani, President and CEO.